[Thoughts about the present state of tumour chemotherapy (author's transl)].
There are some impacts in tumour chemotherapy being worth-while to be discussed. Considering the information received during the Ninth International Congress of Chemotherapy, held in 1975, the author tries to evaluate the present state of clinical tumour chemotherapy from clinical point of view. The modern oncological clinician (oncologist) has to be faced with a lot of new facts, e.g. use of quantitative differences between normal and tumour cells for individualization of therapy, timing of cancer drug administration, new drugs for cancer treatment, mutual inhibition or potentiation of drug's effects, immunotherapy and possible adverse effects of clinically available drugs.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D004336:Drug Antagonism; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D000970:Antineoplastic Agents
Ubersicht. Zum derzeitigen Stand der Tumorchemotherapie (Mit einer Auswertung des IX. Internationalen Chemotherapie-kongresses in London vom 13.-18. Juli 1975)